571 related articles for article (PubMed ID: 19213608)
1. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
[TBL] [Abstract][Full Text] [Related]
2. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
3. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
4. Initial comparison of inverse optimization, modified peripheral technique, and geometric optimization as real-time intraoperative computer planning options for permanent seed implantation of the prostate.
Raben A; Sammons S; Sim S; Chen H; Hanlon A; Sarkar A; Donavanik V; Grebler A; Geltzeiler J; Benge B; Glick A; Jacob D; Koprowski P
Brachytherapy; 2007; 6(4):238-45. PubMed ID: 17991621
[TBL] [Abstract][Full Text] [Related]
5. Anatomy-based inverse planning dose optimization in HDR prostate implant: a toxicity study.
Mahmoudieh A; Tremblay C; Beaulieu L; Lachance B; Harel F; Lessard E; Pouliot J; Vigneault E
Radiother Oncol; 2005 Jun; 75(3):318-24. PubMed ID: 16086913
[TBL] [Abstract][Full Text] [Related]
6. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer.
Zelefsky MJ; Yamada Y; Cohen GN; Shippy A; Chan H; Fridman D; Zaider M
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):65-70. PubMed ID: 17189063
[TBL] [Abstract][Full Text] [Related]
7. Factors predicting for urinary incontinence after prostate brachytherapy.
McElveen TL; Waterman FM; Kim H; Dicker AP
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
[TBL] [Abstract][Full Text] [Related]
8. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
[TBL] [Abstract][Full Text] [Related]
9. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
[TBL] [Abstract][Full Text] [Related]
10. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy.
Ghadjar P; Keller T; Rentsch CA; Isaak B; Behrensmeier F; Stroux A; Thalmann GN; Aebersold DM
Brachytherapy; 2009; 8(1):45-51. PubMed ID: 19038584
[TBL] [Abstract][Full Text] [Related]
11. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
12. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
13. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
14. Four-year experience of interstitial permanent brachytherapy for Japanese men with localized prostate cancer.
Ishiyama H; Satoh T; Kitano M; Tsumura H; Kotani S; Okusa H; Uemae M; Baba S; Hayakawa K
Jpn J Clin Oncol; 2008 Jul; 38(7):469-73. PubMed ID: 18577509
[TBL] [Abstract][Full Text] [Related]
15. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
Lee HK; Adams MT; Motta J
Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
[TBL] [Abstract][Full Text] [Related]
16. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
Potters L; Calugaru E; Jassal A; Presser J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
[TBL] [Abstract][Full Text] [Related]
17. [Permanent implant brachytherapy for early, organ-confined prostate cancer].
Agoston P; Major T; Fröhlich G; Baricza K; Szabó Z; Lövey J; Varjas G; Kásler M; Fodor J; Polgár C
Magy Onkol; 2011 Sep; 55(3):170-7. PubMed ID: 21918742
[TBL] [Abstract][Full Text] [Related]
18. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Fearn PA; Kattan MW; Stock RG
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1472-7. PubMed ID: 17689026
[TBL] [Abstract][Full Text] [Related]
19. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161
[TBL] [Abstract][Full Text] [Related]
20. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
